Macrosalb Medi-Radiopharma

Human Albumin Macroaggregates, the active ingredient in Macrosalb Medi‑Radiopharma, is an albumin macroaggregate presented as a solution for injection for intravenous use. It serves as a diagnostic radiopharmaceutical, providing a radiographic marker for lung perfusion imaging in patients undergoing ventilation‑perfusion (V/Q) scans. The product carries ATC code V09EA02 and is marketed in the European Union for use by nuclear medicine specialists.

GNH USA supplies Macrosalb Medi‑Radiopharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, diagnostic imaging centres and specialized nuclear medicine units worldwide.

Macrosalb Medi‑Radiopharma, a diagnostic radiopharmaceutical, is used in pulmonary perfusion assessment.

- Lung perfusion imaging: enables visualization of regional blood flow in the lungs during a ventilation‑perfusion scan. - Ventilation‑perfusion (V/Q) scan: provides the perfusion component to evaluate suspected pulmonary embolism. - Pre‑operative pulmonary evaluation: assists in assessing lung function before thoracic surgery.

Macrosalb may be associated with the following adverse reactions.

Common Side Effects: - Transient dyspnea: short‑lasting shortness of breath after injection. - Cough: mild, self‑limiting cough. - Chest discomfort: mild pain at the injection site or in the thorax. - Mild fever: low‑grade temperature elevation. - Headache: transient headache. - Nausea: occasional mild nausea.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Pulmonary hypertension: acute rise in pulmonary arterial pressure. - Embolic events: rare obstruction of larger pulmonary vessels. - Severe hypotension: sudden drop in blood pressure. - Acute respiratory distress syndrome (ARDS): rare severe lung inflammation. - Cardiac arrhythmia: uncommon rhythm disturbances.

When using Macrosalb, consider the following precautions.

- Allergy assessment: verify no known hypersensitivity to human albumin or radiopharmaceutical components. - Patient monitoring: observe vital signs and respiratory status during and after administration. - Pregnancy and lactation: use only if the diagnostic benefit outweighs potential fetal or infant risk. - Concomitant imaging agents: avoid administration within 24 hours of other radiopharmaceuticals that may interfere with imaging interpretation. - Cardiopulmonary status: exercise caution in patients with severe pulmonary hypertension or right‑heart failure. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Macrosalb can interact with other substances as follows.

Major Interactions (Avoid): - Other radiopharmaceuticals: concurrent use may cause imaging interference and inaccurate results. - High‑dose iodine contrast agents: may alter lung perfusion imaging if given within 24 hours. - Anticoagulants: may increase the risk of capillary bleeding at the injection site.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may affect pulmonary vascular tone and particle distribution. - Vasodilators: could modify capillary trapping of macroaggregates. - Drugs affecting albumin binding (e.g., high‑dose albumin infusions): may influence particle behavior. - Chemotherapy agents: monitor for additive pulmonary toxicity. - Corticosteroids: may mask early allergic reactions.